The purposes of this study are:
- To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A)
- To measure how much of the Galcanezumab lyophilized (freeze dried) injectable
formulation is absorbed into the blood stream and how long it takes the body to get rid
of it compared to the Galcanezumab solution injectable formulation after a single
injection under the skin (subcutaneous [SC]) (Part B).
Information about any side effects that may occur will also be collected. Each part of the
study will last about six months. Participants may only enroll in one part.